# Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

> **NCT02178241** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 26 (actual)

## Conditions studied

- Metastatic Ureter Carcinoma
- Metastatic Urethral Carcinoma
- Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
- Stage III Ureter Cancer AJCC v7
- Stage III Urethral Cancer AJCC v7
- Stage IV Bladder Urothelial Carcinoma AJCC v7
- Stage IV Ureter Cancer AJCC v7
- Stage IV Urethral Cancer AJCC v7
- Ureter Urothelial Carcinoma
- Urethral Urothelial Carcinoma

## Interventions

- **DRUG:** Eribulin Mesylate
- **DRUG:** Gemcitabine Hydrochloride

## Key facts

- **NCT ID:** NCT02178241
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-11
- **Primary completion:** 2019-03-18
- **Final completion:** 2019-07-11
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2019-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02178241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02178241, "Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02178241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*